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Background
This study investigated mortality rate, early CD4
responses, pattern of ARVs substitutions and medication
adherence of HIV-infected patients on first-line triple
combination ART.
Methods
Assessment of 196 HIV-infected patients on combina-
tion ART regimens was performed after 18 months of
therapy. Medication adherence assessment of 69 follow-
up target groups was based on a study-specific question-
naire. Paired sample t-test and simple linear correlation
were used to test the association of the CD4-cell Counts
at different time intervals. Kaplan-Meier model used to
assess survival functions and the log-rank test was used
to assess statistical difference at 95% CI.
Results
Mean age of participants was 33.6 years (95%CI, 32.05-
35.15); 67.9% were females. At ART initiation, 27.0%
were at WHO stage II, 47.0% at stage III. Mortality
rate (N = 196) was 20.32 deaths per 100 patient-
months; 31.6% occurred in <30 days while 52.6%
occurred post 120 days of treatment. The meanCD4-
cell count (cells/mm
3) at ART initiation was 179.2
which increased to 328.5 at 3 months, 325.6 at 6
months, 357.4 at 12 months, and 366.7 at 18 months,
(p < 0.01). Patients started on Stavudine-based or Efa-
virenz-based regimens were considerably more likely to
have that drug substituted, compared to patients
started on Zidovudine-based or Nevirapine-based regi-
mens. 73.8% level of adherence was reported after 18
months on ART.
Discussion
In this setting, patients receiving ART showed signifi-
cant improvements in CD4-cell status but adherence
level was relatively poor. A large proportion of the
patients presented very late for treatment with very poor
baseline parameters. This finding supports the need for
a rapid scale-up of counselling and testing for early
detection of asymptomatic cases in developing countries.
Patients were more stable on Zidovudine-based or
Nevirapine-based regimens compared to Stavudine-
based or Efavirenz-based regimens. Early mortality rate
was high probably due to poor baseline parameters or
late presentation for treatment, indicating need for early
interventions. The follow-up CD4-cells measurements
were not done every 6 months for all patients eligible
for repeat CD4-cell Count in accordance to the Nigerian
national ART guidelines, hence the need for improve-
ment in the adherence to the national treatment
guideline.
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